The Patients Before Monopolies Act, or PBM Act, would prohibit a person or company from both owning or controlling a pharmacy and owning or controlling an insurance company or pharmacy benefit manager (PBM). The bill is aimed at vertically integrated health care conglomerates that combine PBM, insurer, and pharmacy operations, which the bill says can steer patients to affiliated pharmacies, reduce competition, and raise prescription drug costs. It also cites concerns that these structures may contribute to independent pharmacy closures and allow profits to be shifted in ways that evade medical loss ratio limits.
If enacted, the bill would require any covered entity in violation to divest its pharmacy business within one year. It gives enforcement authority to the FTC and DOJ Antitrust Division, authorizes state attorneys general and private plaintiffs to sue, and allows courts to order divestiture, disgorgement, treble damages, and other equitable relief. The bill also requires FTC/DOJ review of divestitures and future transactions, directs the FTC to issue implementing rules, and mandates quarterly compliance reports to Congress.
The bill would create a new federal structural separation rule for the pharmacy and health insurance/PBM sectors, effectively barring common ownership between pharmacies and entities that provide insurance or PBM services. It would add new federal enforcement mechanisms and remedies, including mandatory divestiture, escrow of profits during noncompliance, private rights of action, state parens patriae actions, and FTC/DOJ review of related transactions under antitrust law. The measure would directly affect large integrated health care companies, PBMs, insurers, affiliated pharmacies, independent pharmacies, consumers, and state and federal antitrust enforcers.
Based on the bill text and the absence of recorded committee debate or votes, the apparent sentiment is strongly pro-competition and pro-consumer, with the bill framed as a response to monopolistic practices in prescription drug distribution. The sponsors from both parties suggest some bipartisan interest in addressing PBM and pharmacy ownership conflicts. No formal vote history or transcript is available here, so there is no recorded opposition or support beyond the bill’s findings and sponsor list.
The main point of contention is the bill’s broad prohibition on common ownership, which would force divestiture of pharmacy assets by companies that also own insurers or PBMs. Supporters are likely to emphasize lower drug costs, protection for patients, and preservation of independent pharmacies, while opponents may argue the bill is overly disruptive, could reduce efficiencies or integrated care coordination, and may create compliance and valuation problems for affected firms. The bill also raises likely debate over federal authority, the scope of FTC/DOJ power, and whether structural separation is the right remedy versus targeted conduct regulation.